SCHEMBL25616772

SCHEMBL25616772

CC(C)(C)[Si](C)(C)NS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 4/20 0.57
▸ CA1 P00915 3/20 0.57
▸ CA12 O43570 2/20 0.57
▸ CA9 Q16790 2/20 0.57
▸ CA3 P07451 1/20 0.57
▸ CA4 P22748 1/20 0.57
▸ CA6 P23280 1/20 0.57
▸ CA5A P35218 1/20 0.57
▸ CA7 P43166 1/20 0.57
▸ CA13 Q8N1Q1 1/20 0.57
▸ CA14 Q9ULX7 1/20 0.57
▸ CA5B Q9Y2D0 1/20 0.57
▸ MMP1 P03956 1/20 0.53
▸ MMP2 P08253 1/20 0.53
▸ MMP9 P14780 1/20 0.53
▸ MMP8 P22894 1/20 0.53
▸ MMP13 P45452 1/20 0.53
▸ EDNRB P24530 2/20 0.49
▸ EDNRA P25101 2/20 0.49
▸ KMT2A Q03164 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29446067 0.84 CA2 (0.58) CA2CA1CA5AMMP1MMP2
SCHEMBL21971206 0.80 GAA (0.52) CA2CA1CA12CA9MMP1
SCHEMBL10680402 0.78 KEAP1 (0.48) CA2CA1MMP1MMP2MMP9
SCHEMBL24029269 0.77 CA2 (0.47) CA2CA1CA12CA9KMT2A
SCHEMBL3046201 0.76 CA2 (0.65) CA2CA1CA12CA9CA3
SCHEMBL23568476 0.76 KMT2A (0.42) KMT2AMEN1ALDH1A1TDP1LMNA
SCHEMBL23851285 0.75 KMT2A (0.54) CA2KMT2AALDH1A1HPGDLMNA
SCHEMBL24978417 0.75 ALDH1A1 (0.43) CA2CA1KMT2AMEN1KDM4E
SCHEMBL30558751 0.75 CA1 (0.49) CA2CA1CA12CA9CA3
SCHEMBL24028363 0.74 KDM1A (0.48) KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4713096-A1 CDK INHIBITOR COMPOUNDS Aleksia Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
WO-2024238574-A1 CDK INHIBITOR COMPOUNDS ALEKSIA THERAPEUTICS, INC. (US) 2024-11-21 — — WO disclosed
CN-116348451-A ENPP1 modulators and uses thereof 维艾尔生物科技有限公司 2023-06-27 — — CN disclosed
US-20230183188-A1 ENPP1 MODULATORS AND USES THEREOF Vir Biotechnology, Inc. 2023-06-15 — — US disclosed
EP-4149927-A1 ENPP1 MODULATORS AND USES THEREOF VIR Biotechnology, Inc. (US) 2023-03-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183188-A1 ENPP1 MODULATORS AND USES THEREOF ENPP1, ENPP2, ENPP3 CA2 4507/4885CA1 4872/4885CA12 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback